147 related articles for article (PubMed ID: 29620290)
1. Significance of Lysyl oxidase‑like 2 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma.
Ninomiya G; Yamada S; Hayashi M; Takeda S; Suenaga M; Takami H; Kanda M; Iwata N; Niwa Y; Tanaka C; Kobayashi D; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2018 Jun; 39(6):2664-2672. PubMed ID: 29620290
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
3. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
Hong X; Yu JJ
Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
[TBL] [Abstract][Full Text] [Related]
4. LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells.
Fan Z; Zheng W; Li H; Wu W; Liu X; Sun Z; Hu H; Du L; Jia Q; Liu Q
Oncol Rep; 2020 May; 43(5):1641-1649. PubMed ID: 32323822
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells.
Lin ZY; Chuang YH; Chuang WL
Biomed Pharmacother; 2012 Oct; 66(7):525-9. PubMed ID: 22739041
[TBL] [Abstract][Full Text] [Related]
6. Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis.
Choi J; Chung T; Rhee H; Kim YJ; Jeon Y; Yoo JE; Noh S; Han DH; Park YN
Gut Liver; 2019 Jan; 13(1):83-92. PubMed ID: 29938458
[TBL] [Abstract][Full Text] [Related]
7. The effect of LOXL2 in hepatocellular carcinoma.
Wu L; Zhang Y; Zhu Y; Cong Q; Xiang Y; Fu L
Mol Med Rep; 2016 Sep; 14(3):1923-32. PubMed ID: 27430160
[TBL] [Abstract][Full Text] [Related]
8.
Yang YL; Tsai MC; Chang YH; Wang CC; Chu PY; Lin HY; Huang YH
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206143
[TBL] [Abstract][Full Text] [Related]
9. Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting.
Radić J; Kožik B; Nikolić I; Kolarov-Bjelobrk I; Vasiljević T; Vranjković B; Despotović S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511503
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
[TBL] [Abstract][Full Text] [Related]
11. Transducin (Beta)-Like 1 X-Linked Receptor 1 Correlates with Clinical Prognosis and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.
Kuang X; Zhu J; Peng Z; Wang J; Chen Z
Dig Dis Sci; 2016 Feb; 61(2):489-500. PubMed ID: 26386862
[TBL] [Abstract][Full Text] [Related]
12. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
13. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
14. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma.
Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H
J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis.
Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS
Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767
[TBL] [Abstract][Full Text] [Related]
16. Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation.
Wu S; Zheng Q; Xing X; Dong Y; Wang Y; You Y; Chen R; Hu C; Chen J; Gao D; Zhao Y; Wang Z; Xue T; Ren Z; Cui J
J Exp Clin Cancer Res; 2018 May; 37(1):99. PubMed ID: 29728125
[TBL] [Abstract][Full Text] [Related]
17. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
Jin Y; Wang J; Han J; Luo D; Sun Z
Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
[TBL] [Abstract][Full Text] [Related]
18. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
[TBL] [Abstract][Full Text] [Related]
19. The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism.
Wu S; Xing X; Wang Y; Zhang X; Li M; Wang M; Wang Z; Chen J; Gao D; Zhao Y; Chen R; Ren Z; Zhang K; Cui J
Eur J Cancer; 2021 Apr; 147():63-73. PubMed ID: 33618200
[TBL] [Abstract][Full Text] [Related]
20. RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling.
Zhou YJ; Yang ML; He X; Gu HY; Ren JH; Cheng ST; Fu Z; Zhang ZZ; Chen J
J Exp Clin Cancer Res; 2024 Feb; 43(1):45. PubMed ID: 38326908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]